


# Reference Data

(Consolidated Financial Results for Q1 FY2013)



Daiichi-Sankyo

July 31, 2013

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

# MEMO

(This page is intentionally left blank)

# Contents

1.	Consolidated Income Statement	P1
2.	Currency Rate	P1
3.	Segment Information	P2
4.	Sales by Business Units	P3
5.	Sales of Global Products	P6
6.	Number of Employees	P7
7.	Consolidated Balance Sheets	P9
8.	Consolidated Statements of Cash Flow	P11
9.	Summary of Product Outlines	P12
10.	Major R&D Pipeline (Innovative pharmaceuticals)	P13

Supplemental Information

Historical Data

## 1. Summary of Consolidated Income Statement

JPY Bn	Q1			Q2			Q3			Q4			Q1					FY2013				
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	to forecast	to sales	Forecast	from May	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>252.5</b>	<b>+4.1%</b>										<b>100%</b>	<b>252.5</b>	<b>9.9</b>	<b>+4.1%</b>	<b>23%</b>	<b>100%</b>	<b>1,080.0</b>	<b>0.0</b>	<b>82.1</b>	<b>+8.2%</b>
Cost of sales	33%	83.7	+25.7%										33%	83.7	17.1	+25.7%	24%	33%	355.0	0.0	41.3	+13.2%
Gross Profit	67%	168.8	-4.1%										67%	168.8	-7.2	-4.1%	23%	67%	725.0	0.0	40.8	+6.0%
SG&A expenses	59%	148.0	+3.2%										59%	148.0	4.6	+3.2%	24%	57%	615.0	0.0	31.3	+5.4%
R&D expenses	20%	50.0	+18.9%										20%	50.0	7.9	+18.9%	27%	17%	187.0	0.0	4.0	+2.2%
A&P expenses	10%	24.7	+8.8%										10%	24.7	2.0	+8.8%			not disclosed			
Personnel expenses	15%	38.2	+10.0%										15%	38.2	3.5	+10.0%			not disclosed			
Other SG&A expenses	14%	35.1	-20.1%										14%	35.1	-8.9	-20.1%			not disclosed			
<b>Operating Income</b>	<b>8%</b>	<b>20.8</b>	<b>-36.2%</b>										<b>8%</b>	<b>20.8</b>	<b>-11.8</b>	<b>-36.2%</b>	<b>19%</b>	<b>10%</b>	<b>110.0</b>	<b>0.0</b>	<b>9.5</b>	<b>+9.4%</b>
Non-operating income / expenses		2.6												2.6	-5.7				-10.0	-10.0	-8.6	
Non-operating income		6.5												6.5	-3.8				not disclosed			
Non-operating expenses		3.9												3.9	2.0				not disclosed			
<b>Ordinary Income</b>	<b>9%</b>	<b>23.3</b>	<b>-42.9%</b>										<b>9%</b>	<b>23.3</b>	<b>-17.5</b>	<b>-42.9%</b>	<b>23%</b>	<b>9%</b>	<b>100.0</b>	<b>-10.0</b>	<b>0.9</b>	<b>+0.9%</b>
Extraordinary income / losses		-10.1												-10.1	-10.6				7.0	2.0	14.1	
Extraordinary income		1.6												1.6	-0.4				not disclosed			
Extraordinary losses		11.7												11.7	10.2				not disclosed			
Income before income taxes and minority interests	5%	13.2	-68.0%										5%	13.2	-28.2	-68.0%	12%	10%	107.0	-8.0	14.9	+16.2%
Income taxes / minority interests		2.2												2.2	-18.8				42.0	-5.0	16.5	
Income taxes		1.9												1.9	-14.9				not disclosed			
Minority interests		0.3												0.3	-3.9				not disclosed			
<b>Net Income</b>	<b>4%</b>	<b>11.0</b>	<b>-46.0%</b>										<b>4%</b>	<b>11.0</b>	<b>-9.4</b>	<b>-46.0%</b>	<b>17%</b>	<b>6%</b>	<b>65.0</b>	<b>-3.0</b>	<b>-1.6</b>	<b>-2.4%</b>
Effective tax rate		15%												15%								
Overseas sales ratio results		53%												53%								

### Notes to FY2013 Q1 Results Year-on-Year Comparisons

Net Sales { Japan company +8.4 (Nexium +9.3, Memary +1.5, Vaccines +2.8), Daiichi Sankyo Inc. +10.7 (Olmesartan +6.8), Daiichi Sankyo Europe +5.1 (Olmesartan +4.5), ASCA company +4.1  
Ranbaxy -16.8, Luitpold -3.3

Currency impact (appreciation of JPY to USD and EUR +15.0, appreciation of JPY to INR +3.0)

SG&A expenses R&D: Currency impact (appreciation of JPY to USD, EUR, and INR +6.0) Other: Currency impact (appreciation of JPY to USD, EUR, and INR +8.5)

Extraordinary losses Loss on business restructuring in EU etc. +10.0

Income taxes Dividend received from U3 Pharma is considered as devaluation of book value resulting in benefit of 3.7 billion yen in tax expenses.

### Notes to revision of FY2013 Forecast

Ordinary Income Owing to depreciation in the Indian rupee against the US dollar, loss on valuation of derivatives at Ranbaxy is expected to be recorded in the second quarter.

Net Income Gain on sales of unutilized assets etc. are projected

## 2. Currency Rate

	Q1			Q2 YTD			Q3 YTD			Q4 YTD			Q1		FY2013	
	Results	Results	YoY	Results	Results	YoY	Results	Results	YoY	Results	Results	YoY	Forecast	from May	YoY	YoY
USD/JPY (average)	98.76												98.76	+18.55	95.94	0.94
EUR/JPY (average)	128.96												128.96	+26.05	125.99	0.99
INR/JPY (average)	1.71												1.71	+0.12	1.70	-0.05

Appreciation of JPY to USD, EUR, and INR positively affected the FY2013 Q1 results by 18.0 bil yen in net sales and 0.5 bil yen in operating income.

Annual impact of one yen change is estimated to affect the group's FY2013 performance by; USD: net sales 2.0 bil yen, operating income minor / EUR: net sales 0.6 bil yen, operating income minor

### 3. Segment Information

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			Q1				
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	
Sales to outside customers		210.2	+14.6%											210.2	26.7	+14.6%	
Inter-segment sales		0.4												0.4	0.1		
<b>Net sales</b>	<b>100%</b>	<b>210.6</b>	<b>+14.6%</b>											<b>100%</b>	<b>210.6</b>	<b>26.8</b>	<b>+14.6%</b>
Cost of sales	29%	61.9	+29.2%											29%	61.9	14.0	+29.2%
Gross Profit	71%	148.7	+9.4%											71%	148.7	12.8	+9.4%
SG&A expenses	61%	127.4	+10.0%											61%	127.4	11.6	+10.0%
R&D expenses	23%	47.7	+18.3%											23%	47.7	7.4	+18.3%
Other expenses	38%	79.8	+5.5%											38%	79.8	4.2	+5.5%
<b>Operating Income</b>	<b>10%</b>	<b>21.3</b>	<b>+6.1%</b>											<b>10%</b>	<b>21.3</b>	<b>1.2</b>	<b>+6.1%</b>
Non-operating income		2.0												2.0	-0.1		
Non-operating expenses		0.5												0.5	-0.5		
<b>Ordinary Income</b>	<b>11%</b>	<b>22.7</b>	<b>+7.8%</b>											<b>11%</b>	<b>22.7</b>	<b>1.7</b>	<b>+7.8%</b>
Extraordinary income		1.2												1.2	-0.8		
Extraordinary losses		11.5												11.5	10.2		
Income before income taxes and minority interests	6%	12.5	-42.8%											6%	12.5	-9.3	-42.8%
Income taxes		2.2												2.2	-5.9		
Minority interests		-0.4												-0.4	-0.3		
<b>Net Income</b>	<b>5%</b>	<b>10.6</b>	<b>-22.7%</b>											<b>5%</b>	<b>10.6</b>	<b>-3.1</b>	<b>-22.7%</b>

#### Ranbaxy Group

Sales to outside customers		42.3	-28.4%											42.3	-16.8	-28.4%	
Inter-segment sales		0.3												0.3	-0.4		
<b>Net sales</b>	<b>100%</b>	<b>42.6</b>	<b>-28.8%</b>											<b>100%</b>	<b>42.6</b>	<b>-17.2</b>	<b>-28.8%</b>
Cost of sales	52%	22.3	+14.5%											52%	22.3	2.8	+14.5%
Gross Profit	48%	20.3	-49.6%											48%	20.3	-20.0	-49.6%
SG&A expenses	46%	19.5	-26.3%											46%	19.5	-7.0	-26.3%
R&D expenses	6%	2.6	+28.2%											6%	2.6	0.6	+28.2%
Other expenses	40%	17.0	-30.8%											40%	17.0	-7.5	-30.8%
<b>Operating Income</b>	<b>2%</b>	<b>0.8</b>	<b>-94.4%</b>											<b>2%</b>	<b>0.8</b>	<b>-13.1</b>	<b>-94.4%</b>
Non-operating income		4.6												4.6	-3.7		
Non-operating expenses		3.4												3.4	2.5		
<b>Ordinary Income</b>	<b>5%</b>	<b>2.0</b>	<b>-90.8%</b>											<b>5%</b>	<b>2.0</b>	<b>-19.3</b>	<b>-90.8%</b>
Extraordinary income		0.3												0.3	0.3		
Extraordinary losses		0.2												0.2	0.0		
Income before income taxes and minority interests	5%	2.1	-90.0%											5%	2.1	-19.0	-90.0%
Income taxes		-0.5												-0.5	-6.6		
Minority interests		0.1												0.1	-0.0		
<b>Net Income</b>	<b>6%</b>	<b>2.5</b>	<b>-83.0%</b>											<b>6%</b>	<b>2.5</b>	<b>-12.5</b>	<b>-83.0%</b>

#### Inter-segment Transactions

<b>Net sales</b>		<b>-0.7</b>												<b>-0.7</b>		
Cost of sales		-0.4												-0.4		
Gross Profit		-0.3												-0.3		
SG&A expenses		1.0												1.0		
R&D expenses		-0.3												-0.3		
Other expenses		1.3												1.3		
<b>Operating Income</b>		<b>-1.3</b>												<b>-1.3</b>		
Non-operating income		-0.1												-0.1		
Non-operating expenses		0.0												0.0		
<b>Ordinary Income</b>		<b>-1.4</b>												<b>-1.4</b>		
Extraordinary income		0												-		
Extraordinary losses		0.0												0.0		
Income before income taxes and minority interests		-1.3												-1.3		
Income taxes		0.2												0.2		
Minority interests		0.6												0.6		
<b>Net Income</b>		<b>-2.1</b>												<b>-2.1</b>		

#### 4. Sales by Business Units

	FY2013 Plan	Q1			Q2			Q3			Q4			Q1				
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																		
<b>Consolidated Net Sales</b>	<b>1,080.0</b>	<b>252.5</b>	<b>+4.1%</b>	<b>23%</b>									<b>252.5</b>	<b>9.9</b>	<b>+4.1%</b>	<b>23%</b>		
<b>Japan Company (domestic sales)</b>	<b>480.0</b>	<b>106.6</b>	<b>+8.6%</b>	<b>22%</b>									<b>106.6</b>	<b>8.4</b>	<b>+8.6%</b>	<b>22%</b>		
Olmotec	81.0	16.6	-8.9%	21%									16.6	-1.6	-8.9%	21%		
Rezaltas	24.0	4.3	+9.6%	18%									4.3	0.4	+9.6%	18%		
Calblock	9.0	2.4	-11.1%	27%									2.4	-0.3	-11.1%	27%		
Loxonin	61.0	14.9	+5.8%	25%									14.9	0.8	+5.8%	25%		
Cravit	36.0	7.6	-5.4%	21%									7.6	-0.4	-5.4%	21%		
Nexium	38.0	10.9	+562.1%	29%									10.9	9.3	+562.1%	29%		
Memary	36.0	6.6	+28.7%	18%									6.6	1.5	+28.7%	18%		
Mevalotin	23.0	5.2	-20.5%	23%									5.2	-1.3	-20.5%	23%		
Artist	22.0	5.4	-3.4%	25%									5.4	-0.2	-3.4%	25%		
Omnipaque	19.0	4.7	-4.0%	25%									4.7	-0.2	-4.0%	25%		
Urief	12.0	2.7	+0.1%	22%									2.7	0.0	+0.1%	22%		
Inavir	10.0	0.3	-38.8%	3%									0.3	-0.2	-38.8%	3%		
Ranmark	6.0	1.6	+162.8%	26%									1.6	1.0	+162.8%	26%		
Vaccines	not disclosed	8.0	+53.9%	-									8.0	2.8	+53.9%	-		
Daiichi Sankyo Espha products	not disclosed	2.9	+3.6%	-									2.9	0.1	+3.6%	-		
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>48.0</b>	<b>9.8</b>	<b>-4.6%</b>	<b>20%</b>									<b>9.8</b>	<b>-0.5</b>	<b>-4.6%</b>	<b>20%</b>		
<b>Daiichi Sankyo, Inc. (US)</b>	<b>150.0</b>	<b>46.6</b>	<b>+29.7%</b>	<b>31%</b>									<b>46.6</b>	<b>10.7</b>	<b>+29.7%</b>	<b>31%</b>		
Olmesartan	86.0	30.7	+28.4%	36%									30.7	6.8	+28.4%	36%		
Benicar/Benicar HCT	67.0	23.8	+26.1%	36%									23.8	4.9	+26.1%	36%		
Azor	12.0	4.6	+31.6%	38%									4.6	1.1	+31.6%	38%		
Tribenzor	6.0	2.3	+49.3%	39%									2.3	0.8	+49.3%	39%		
Welchol	46.0	11.4	+37.4%	25%									11.4	3.1	+37.4%	25%		
Effient (alliance revenue)	not disclosed	4.0	+65.0%	-									4.0	1.6	+65.0%	-		
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>40.0</b>	<b>8.1</b>	<b>-28.7%</b>	<b>20%</b>									<b>8.1</b>	<b>-3.3</b>	<b>-28.7%</b>	<b>20%</b>		
Venofer	19.0	4.9	-27.7%	26%									4.9	-1.9	-27.7%	26%		
<b>Daiichi Sankyo Europe GmbH</b>	<b>73.0</b>	<b>19.0</b>	<b>+36.8%</b>	<b>26%</b>									<b>19.0</b>	<b>5.1</b>	<b>+36.8%</b>	<b>26%</b>		
Olmesartan	56.0	14.4	+45.0%	26%									14.4	4.5	+45.0%	26%		
Olmotec/Olmotec Plus	37.0	9.8	+52.4%	26%									9.8	3.4	+52.4%	26%		
Sevikar	11.0	3.0	+19.5%	27%									3.0	0.5	+19.5%	27%		
Sevikar HCT	7.0	1.6	+62.2%	23%									1.6	0.6	+62.2%	23%		
Effient (alliance revenue)	not disclosed	1.2	+30.3%	-									1.2	-	+30.3%	-		

	FY2013 Plan	Q1			Q2			Q3			Q4			Q1			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
<b>Asia, South and Central America (ASCA)</b>	<b>46.0</b>	<b>11.2</b>	<b>+58.5%</b>	<b>24%</b>									<b>11.2</b>	<b>4.1</b>	<b>+58.5%</b>	<b>24%</b>	
Daiichi Sankyo China	not disclosed	4.7	+77.3%	-									4.7	2.1	+77.3%	-	
Daiichi Sankyo Taiwan	not disclosed	1.1	+40.0%	-									1.1	0.3	+40.0%	-	
Daiichi Sankyo Korea	not disclosed	1.8	+44.6%	-									1.8	0.6	+44.6%	-	
Daiichi Sankyo (Thailand)	not disclosed	0.4	+46.7%	-									0.4	0.1	+46.7%	-	
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.7	+40.8%	-									1.7	0.5	+40.8%	-	
Daiichi Sankyo Venezuela	not disclosed	1.3	+48.4%	-									1.3	0.4	+48.4%	-	
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	0.2	+188.6%	-									0.2	0.1	+188.6%	-	
<b>Ranbaxy Laboratories Limited</b>	<b>217.0</b>	<b>42.3</b>	<b>-28.4%</b>	<b>20%</b>									<b>42.3</b>	<b>-16.8</b>	<b>-28.4%</b>	<b>20%</b>	
<b>Others</b>	<b>26.0</b>	<b>8.9</b>	<b>+30.3%</b>	<b>34%</b>									<b>8.9</b>	<b>2.1</b>	<b>+30.3%</b>	<b>34%</b>	

		Q1 Results			Q2 YTD Results			Q3 YTD Results			Q4 YTD Results			FY2013 Forecast			
		USD	EUR	INR	USD	EUR	INR	USD	EUR	INR	USD	EUR	INR	USD	EUR	INR	
<u>Currency rate YoY comparison</u>	FY2012	80.21	102.91	1.59									May 13	95.00	125.00	1.75	
	FY2013	98.76	128.96	1.71									Jul. 31	95.94	125.99	1.70	
	YoY	18.55	26.05	0.12										0.94	0.99	-0.05	
<u>Currency rate impact (Bn yen)</u>	Nes Sales	about +18.0 Bn yen															
	Operating Income	about +0.5 Bn yen															
<u>New Product Launches</u>		Jun 2013: Pralia (anti-RANKL antibody for the treatment of osteoporosis) launched in Japan.															

**[Reference] Sales in Local Currency**

	FY2013 Plan	Q1			Q2			Q3			Q4			Q1			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
USD Mn																	
<b>Daiichi Sankyo, Inc. (US)</b>	<b>1,579</b>	<b>472</b>	<b>+5.3%</b>	<b>30%</b>									<b>472</b>	<b>24</b>	<b>+5.3%</b>	<b>30%</b>	
Olmesartan	905	311	+4.3%	34%									311	13	+4.3%	34%	
Benicar/Benicar HCT	705	241	+2.4%	34%									241	6	+2.4%	34%	
Azor	126	47	+6.9%	37%									47	3	+6.9%	37%	
Tribenzor	63	23	+21.3%	37%									23	4	+21.3%	37%	
Welchol	484	115	+11.6%	24%									115	12	+11.6%	24%	
Effient (alliance revenue)	not disclosed	41	+34.0%	-									41	10	+34.0%	-	
USD Mn																	
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>421</b>	<b>82</b>	<b>-42.1%</b>	<b>20%</b>									<b>82</b>	<b>-60</b>	<b>-42.1%</b>	<b>20%</b>	
Venofer	200	50	-41.2%	25%									50	-35	-41.2%	25%	
EUR Mn																	
<b>Daiichi Sankyo Europe GmbH</b>	<b>584</b>	<b>147</b>	<b>+9.2%</b>	<b>25%</b>									<b>147</b>	<b>12</b>	<b>+9.2%</b>	<b>25%</b>	
Olmesartan	448	111	+15.7%	25%									111	15	+15.7%	25%	
Olmetec/Olmetec Plus	296	76	+21.6%	26%									76	13	+21.6%	26%	
Sevikar	88	23	-4.6%	27%									23	-1	-4.6%	27%	
Sevikar HCT	56	12	+29.4%	22%									12	3	+29.4%	22%	
Efient (alliance revenue)	not disclosed	9	+4.0%	-									9	-	+4.0%	-	
INR Bn																	
<b>Ranbaxy Laboratories Limited</b>	<b>120</b>	<b>25</b>	<b>-33.5%</b>	<b>21%</b>									<b>25</b>	<b>-12</b>	<b>-33.5%</b>	<b>21%</b>	



**5. Sales of Global Products**

	FY2013 Plan	Q1			Q2			Q3			Q4			Q1				
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																		
<b>Olmесartan</b>	<b>269.0</b>	<b>71.4</b>	<b>+19.0%</b>	<b>27%</b>									<b>71.4</b>	<b>11.4</b>	<b>+19.0%</b>	<b>27%</b>		
Olmotec (JPN)	81.0	16.6	-8.9%	21%									16.6	-1.6	-8.9%	21%		
Rezaltas (JPN)	24.0	4.3	+9.6%	18%									4.3	0.4	+9.6%	18%		
Benicar/Benicar HCT (US)	67.0	23.8	+26.1%	36%									23.8	4.9	+26.1%	36%		
Azor (US)	12.0	4.6	+31.6%	38%									4.6	1.1	+31.6%	38%		
Tribenzor (US)	6.0	2.3	+49.3%	39%									2.3	0.8	+49.3%	39%		
Olmotec/Olmotec Plus (EU)	37.0	9.8	+52.4%	26%									9.8	3.4	+52.4%	26%		
Sevikar (EU)	11.0	3.0	+19.5%	27%									3.0	0.5	+19.5%	27%		
Sevikar HCT (EU)	7.0	1.6	+62.2%	23%									1.6	0.6	+62.2%	23%		
Other subsidiaries, export, etc	24.0	5.4	+35.4%	23%									5.4	1.4	+35.4%	23%		
<b>Prasugrel</b>	<b>not disclosed</b>	<b>5.2</b>	<b>+55.6%</b>	<b>-</b>									<b>5.2</b>	<b>1.8</b>	<b>+55.6%</b>	<b>-</b>		
Effient alliance revenue (US)	not disclosed	4.0	+65.0%	-									4.0	1.6	+65.0%	-		
Effient alliance revenue (EU)	not disclosed	1.2	+30.3%	-									1.2	0.3	+30.3%	-		

**6. Number of Employees**

	Mar 2013 Results	Jun 2013 Results	Sep 2013 Results	Dec 2013 Results	Mar 2014 Results
<b><u>Total Number of Employees</u></b>	<b>32,229</b>	<b>32,402</b>			
Japan	9,251	9,379			
* Overseas	22,978	23,023			
Daiichi Sankyo Group	17,528	17,716			
* Ranbaxy Group	14,701	14,686			

\* For overseas subsidiaries with different fiscal year-ends, numbers as of Mar-end are shown in the June-end columns

# MEMO

(This page is intentionally left blank)

## 7. Consolidated Balance Sheets

(Billions of yen)

	Mar 2013	Jun 2013	QoQ	Notes
<b>ASSETS</b>				
Current assets				
Cash and time deposits	161.0	161.7	0.7	PBT +13.2 Bn, Depreciation and amortization +11.6 Bn Net decrease in notes and accounts receivable +18.8 Bn Income taxes paid -22.3 Bn , Dividend paid -21.1 Bn Net purchase and acquisitions of proceeds from sales of non-current assets -10.0 Bn
Trade notes and accounts receivable	238.5	228.6	-9.9	
Marketable securities	211.3	199.5	-11.9	
Inventories	174.4	184.3	9.9	
Deferred tax assets	111.1	115.1	3.9	
Other current assets	50.0	56.3	6.3	
Allowance for doubtful accounts	-2.7	-3.0	-0.3	
Total current assets	943.6	942.4	-1.2	
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	138.3	138.7	0.4	
Machinery, equipment and vehicles, net	63.5	65.9	2.5	
Land	35.8	36.7	0.9	
Construction in progress	47.9	53.9	6.1	
Other, net	18.0	20.5	2.5	
Total property, plant and equipment	303.4	315.7	12.3	Newly added: Daichi Sankyo +5.0 Bn
Intangible assets				
Goodwill, net	73.5	72.1	-1.4	
Other intangible assets, net	149.9	154.7	4.8	
Total intangible assets	223.5	226.8	3.3	
Investments and other assets				
Investment securities	129.2	133.0	3.8	
Deferred tax assets	32.5	35.2	2.6	
Other	12.1	12.9	0.7	
Allowance for doubtful accounts	-0.3	-0.3	0.0	
Total investments and other assets	173.5	180.7	7.1	
Total non-current assets	700.4	723.2	22.8	
<b>Total assets</b>	<b>1,644.1</b>	<b>1,665.6</b>	<b>21.5</b>	

(Billions of yen)

	Mar 2013	Jun 2013	QoQ	Notes
<b>LIABILITIES</b>				
Current liabilities				
Trade notes and accounts payable	59.8	65.6	5.8	
Short-term loans payable	66.1	64.0	-2.1	
Current portion of bonds	0.0	60.0	60.0	Transferred from long-term liabilities : Daiichi Sankyo +60.0 Bn
Income taxes payable	23.2	4.3	-19.0	
Provision for settlement expenses	43.7	47.9	4.2	
Provision for restructuring loss	0.0	10.1	10.1	
Allowance for sales returns	0.6	2.3	1.7	
Allowance for sales rebates	2.0	1.9	0.0	
Provision for environment measures	1.3	0.6	-0.7	
Accrued expenses	89.0	118.0	29.0	
Other current liabilities	150.4	124.7	-25.6	
<b>Total current liabilities</b>	<b>436.1</b>	<b>499.5</b>	<b>63.4</b>	
Long-term liabilities				
Bonds payable	107.9	48.7	-59.2	Transferred to current liabilities : Daiichi Sankyo -60.0 Bn
Long-term loans payable	93.0	95.2	2.2	
Deferred tax liabilities	45.1	47.0	1.9	
Accrued employees' severance and retirement benefits	13.9	12.4	-1.5	
Accrued directors' severance and retirement benefits	0.2	0.2	0.0	
Other long-term liabilities	32.1	34.9	2.8	
<b>Total long-term liabilities</b>	<b>292.2</b>	<b>238.4</b>	<b>-53.9</b>	
<b>Total liabilities</b>	<b>728.3</b>	<b>737.8</b>	<b>9.5</b>	
<b>NET ASSETS</b>				
Shareholders' equity				
Common stock	50.0	50.0	0.0	
Capital surplus	105.2	105.2	0.0	
Retained earnings	766.7	756.6	-10.1	Net income +11.0 Bn, Dividend paid -21.1 Bn
Treasury stock, at cost	-14.5	-14.5	0.0	
<b>Total shareholders' equity</b>	<b>907.5</b>	<b>897.4</b>	<b>-10.1</b>	
Accumulated other comprehensive income				
Net unrealized gain on investment securities	34.2	35.7	1.5	
Deferred gains or losses on hedges	0.9	1.0	0.0	
Foreign currency translation adjustments	-60.0	-41.8	18.1	Increase in net assets of overseas subsidiaries on a JPY basis +18.1 Bn
<b>Total accumulated other comprehensive income</b>	<b>-24.8</b>	<b>-5.2</b>	<b>19.7</b>	
Subscription rights to shares	4.1	4.4	0.3	
Minority interests	29.0	31.1	2.1	Ranbaxy +2.5 Bn
<b>Total net assets</b>	<b>915.7</b>	<b>927.8</b>	<b>12.0</b>	
<b>Total liabilities and net assets</b>	<b>1,644.1</b>	<b>1,665.6</b>	<b>21.5</b>	

## 8. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2012 Q1 Results	FY2013 Q1 Results	YoY	Notes
Cash flows from operating activities				
Income before income taxes and minority interests	41.4	13.2	-28.2	
Depreciation and amortization of goodwill	12.9	14.4	1.5	
Increase/decrease in trade receivable and payable	-1.2	15.6	16.8	
Other, net	-5.2	-6.9	-1.7	
Income taxes paid	-9.7	-22.4	-12.7	
Net cash provided by operating activities	38.2	13.9	-24.3	
Cash flows from investing activities				
Net (increase) decrease in short-term investments	-75.3	-12.8	62.5	
(Acquisition of) proceeds from sales of non-current assets	-17.5	-10.1	7.4	
Acquisition of investments in subsidiaries	0.0	—	0.0	
Other, net	4.5	-1.5	-6.0	
Net cash used in investing activities	-88.3	-24.3	63.9	
Cash flows from financing activities				
Net increase (decrease) in loans payable	-2.5	-6.2	-3.6	
Dividends paid	-21.1	-21.1	0.0	
Other, net	0.1	-0.2	-0.3	
Net cash used in financing activities	-23.6	-27.6	-3.9	
Effect of exchange rate changes on cash and cash equivalents	-0.6	7.6	8.2	
Net increase (decrease) in cash and cash equivalents	-74.3	-30.4	43.9	
Cash and cash equivalents, beginning of period	212.7	190.9	-21.8	
Cash and cash equivalents, at end of period	138.4	160.5	22.1	

## 9. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
<b>Japan Company (domestic sales)</b>					
Olmetec	olmesartan	antihypertensive	2004	Daiichi Sankyo	
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
Memory	memantine	treatment for Alzheimer's Disease	2011	Merz	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Ranmark	denosumab	anti-RANKL antibody	2012	Amgen	AstraZeneca
Pralia	denosumab	anti-RANKL antibody	2013	Amgen	
Tenelia	teneligliptin	type 2 diabetes	2012	Mitsubishi Tanabe	Mitsubishi Tanabe
<b>Daiichi Sankyo, Inc. (US)</b>					
Olmesartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo	
Azor	olmesartan / amlodipine		2007		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
<b>Luitpold Pharmaceuticals, Inc. (US)</b>					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
<b>Daiichi Sankyo Europe GmbH</b>					
Olmesartan					
Olmetec	olmesartan		2002		
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini Pfizer Nycomed
Sevikar	olmesartan / amlodipine		2009		
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly

**10. Major R&D Pipeline (Innovative pharmaceuticals)**

As of July, 2013

◆ **Launched/Approved**

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
AMG 162	denosumab	Anti-RANKL antibody	Osteoporosis	JP Launched	Launched in Jun 2013
<p>The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April 2012 as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors, and in June 2013 as treatment for osteoporosis.</p>					

◆ **Filed**

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic	JP Filed	Filed in Nov 2012
<p>The long-acting neuraminidase inhibitor developed and produced by Daiichi Sankyo. This is an inhalant that will act directly on the pulmonary and tracheal sites of infection. Launched in Japan in October 2010 as treatment for influenza A and influenza B viruses.</p>					
CS-747	prasugrel	Anti-platelet agent	Ischemic heart disease undergoing PCI	JP Filed	Filed in Jun 2013
<p>The oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Ltd. Prasugrel helps keep blood platelets from clumping together and developing a blockage in an artery</p>					



◆ Under development (Phase1-3)

Project code Number	Generic Name	Class	Target indication	Stage	Remarks	
DU-176b	edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	Global	P3	Application to be expected in 2H FY2013
			Venous thromboembolism (VTE)	Global	P3	Application to be expected in 2H FY2013
CS-747	prasugrel	Anti-platelet agent	Ischemic Stroke	JP	P3	Study to be completed in FY2014
			Sickle cell disease	US	P3	
AMG 162	denosumab	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	
			Rheumatoid arthritis	JP	P2	
			Giant cell tumor	JP	P2	
DR-3355	levofloxacin	New quinolone	Anti-infection	JP	P3	
ARQ 197	tivantinib	MET inhibitor	Hepatocellular cancer	US/EU	P3	
			Colorectal cancer	US/EU	P2	
DE-766	nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P3	
			Non small cell lung cancer	JP	P3	
			Esophageal cancer	JP	P1	
CS-3150	-	MR antagonist	Hypertension	JP	P2	
			Diabetic nephropathy	JP	P2	
CS-1008	tigatuzumab	Anti-DR5 antibody	Hepatocellular cancer	Global	P2	
U3-1287	patritumab	Anti-HER3 antibody	Non small cell lung cancer	US/EU	P2	
			Non small cell lung cancer	JP	P1	
			Breast cancer	US	P2	
			Breast cancer	JP	P1	
PLX4032	vemurafenib	BRAF inhibitor	Thyroid cancer	US/EU	P2	
PLX3397	-	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma	US	P2	
			Acute myeloid leukemia	US	P2	
			Glioblastoma	US	P2	
			Prostate Cancer	US	P2	
DS-5565	-	$\alpha 2\delta$ ligand	Chronic pain	Global	P2	
SUN13837	-	Modulator of bFGF signaling system	Spinal cord injury	US/EU	P2	
ASB17061	-	Chymase inhibitor	Atopic Dermatitis	US	P2	
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza	US/EU	P2	

◆ Under development (Phase1-3)

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
DS-7309	-	Glucokinase activator	Diabetes	- P1	
DS-8500	-	GPR119 agonist	Diabetes	- P1	
DS-1442	-	CETP inhibitor	Dyslipidemia	- P1	
DS-1040	-	TAF1a inhibitor	Acute ischemic stroke	- P1	
U3-1565	-	Anti-HB-EGF antibody	Solid cancer	US/JP P1	
DS-2248	-	HSP90 inhibitor	Solid cancer	US P1	
DS-7423	-	PI3K/mTOR inhibitor	Solid cancer	US/JP P1	
DS-3078	-	mTOR inhibitor	Solid cancer, lymphoma	US/EU P1	
DS-3032	-	MDM2 inhibitor	Solid cancer, lymphoma	US P1	
DS-8587	-	Topoisomerase inhibitor	Anti-bacterial	- P1	
CS-4771	-	TLR4 inhibitor	Anti-sepsis	- P1	
PLX5622	-	FMS kinase inhibitor	Rheumatoid arthritis	- P1	
CS-0777	-	S1P receptor modulator	Immunomodulator	- P1	
DS-7113	hydromorphone	opioid mu-receptor regulator	Cancer pain	- P1	

◆ Change of stage from announcement in Jan 2013




Project code Number	Generic Name	Class	Target indication	Stage	
AMG 162	denosumab	Anti-RANKL antibody	Osteoporosis	JP	Launched
CS-747	prasugrel	Anti-platelet agent	Ischemic heart disease undergoing PCI	JP	Filed
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza	US/EU	P2
DS-3032	-	MDM2 inhibitor	Solid cancer, lymphoma	US	P1

◆ Discontinue

Project code Number	Generic Name	Class	Target indication	Stage	
DS-7250	-	DGAT1 inhibitor	Diabetes	JP	P2
			Diabetes, Obesity	US/EU	P1
<Reason for discontinue> Daiichi Sankyo decided to discontinue the development of DS-7250 after reviewing its clinical studies results.					
CS-7017	efatutazone	PPAR-gamma agonist	Non small cell lung cancer, Colorectal cancer	US/EU	P2
			Non small cell lung cancer, Colorectal cancer	Asia/JP	P1
<Reason for discontinue> Daiichi Sankyo decided to suspend further in house development of CS-7017 following the review of its clinical studies data results, however will continue to support external development of this compound					
DS-6930	-	Selective PPAR-gamma modulator	Diabetes	-	P1
<Reason for discontinue> Daiichi Sankyo decided to discontinue the development of DS-6930 after reviewing its clinical studies results.					

◆ Major R&D Pipeline Table

As of July, 2013

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular - Metabolics	<p><b>DS-7309</b> (Anti-diabetes / Glucokinase activator)</p> <p><del><b>DS-6930</b> (Anti-diabetes / Selective PPAR-gamma modulator)</del></p> <p><b>DS-8500</b> (Anti-diabetes / GPR119 agonist)</p> <p><b>DS-1442</b> (Dyslipidemia / CETP inhibitor)</p> <p><b>DS-1040</b> (Acute ischemic stroke / TAF1a inhibitor)</p>	<p><b>CS-3150 (JP)</b> (Anti-hypertension / Diabetic nephropathy / MR antagonist)</p> <p><del><b>DS-7250 (JP)</b> (Anti-diabetes / DGAT1 inhibitor)</del></p>	<p><b>DU-176b (Global)</b> (edoxaban / AF / oral factor Xa inhibitor)</p> <p><b>DU-176b (Global)</b> (edoxaban / VTE / oral factor Xa inhibitor)</p> <p></p> <p><b>CS-747 (JP)</b> (prasugrel / ischemic stroke / anti-platelet agent)</p> <p><b>CS-747 (US)</b> (prasugrel / Sickle cell disease / anti-platelet agent)</p>	<p><b>CS-747 (JP)</b> (prasugrel / PCI / anti-platelet agent)</p>
Oncology	<p><b>U3-1565 (US/JP)</b> (Anti-HB-EGF antibody)</p> <p><b>DS-2248 (US)</b> (HSP90 inhibitor)</p> <p><b>DS-7423 (US/JP)</b> (PI3K/mTOR inhibitor)</p> <p><b>DS-3078 (US/EU)</b> (mTOR inhibitor)</p> <p><b>DS-3032 (US)</b> (MDM2 inhibitor)</p>	<p><b>CS-1008 (Global)</b> (tigatuzumab / anti-DR5 antibody)</p> <p><del><b>CS-7017 (US/EU)</b> (efatutazone / PPARγ agonist)</del></p> <p><b>U3-1287 (US/EU)</b> (patritumab / anti-HER3 antibody)</p> <p><b>PLX4032 (US/EU)</b> (vemurafenib / BRAF inhibitor)</p> <p><b>PLX3397 (US)</b> (Fms/Kit/Flt3-ITD inhibitor)</p>	<p><b>ARQ 197 (US/EU)</b> (tivantinib / HCC / MET inhibitor)</p> <p><b>AMG 162 (JP)</b> (denosumab / breast cancer adjuvant / anti-RANKL antibody)</p> <p><b>DE-766 (JP)</b> (nimotuzumab / NSCLC / anti-EGFR antibody)</p> <p><b>DE-766 (JP)</b> (nimotuzumab / Gastric cancer / anti-EGFR antibody)</p>	
Others	<p></p> <p><b>DS-8587</b> (Anti-bacterial / Topoisomerase inhibitor )</p> <p><b>CS-4771</b> (Anti-sepsis / TLR4 inhibitor)</p> <p><b>PLX5622</b> (Rheumatoid arthritis / FMS kinase inhibitor)</p> <p><b>CS-0777</b> (Immunomodulator / S1P receptor modulator)</p> <p><b>DS-7113</b> (hydromorphone / Cancer pain/ opioid mu-receptor regulator )</p>	<p></p> <p><b>CS-8958 (US/EU)</b> (laninamivir / anti-influenza / Outlicensing with Biota)</p> <p><b>AMG 162 (JP)</b> (denosumab / Rheumatoid arthritis / anti-RANKL antibody)</p> <p><b>DS-5565 (Global)</b> (Chronic pain / α2δ ligand)</p> <p><b>SUN13837 (US/EU)</b> (Spinal cord injury / Modulator of bFGF signaling system)</p> <p><b>ASB17061 (US)</b> (Atopic Dermatitis / chymase inhibitor)</p>	<p><b>DR-3355 (JP)</b> (levofloxacin / anti-infection / New quinolone)</p>	<p><b>CS-8958 (JP)</b> (laninamivir / anti-influenza, prophylactic / Neuraminidase inhibitor)</p>

## Cardiovascular-Metabolics

[ Project after Phase 2 ]

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DU-176b	edoxaban	Oral	Factor Xa inhibitor	Atrial fibrillation (AF) Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana(JP)
<ul style="list-style-type: none"> <li>• An oral anticoagulant that specifically, reversibly and directly inhibits Xa factor playing an important role in the process when blood coagulates.</li> <li>• An oral factor Xa inhibitor, possible once daily regimen with high oral absorption, confirmed by clinical trials.</li> <li>• No severe hepatotoxicity signals in pre-clinical and clinical trials</li> <li>• [JP] Launched for the prevention of VTE after major orthopedic surgery in July-2011. Brand name: Lixiana</li> <li>• Development by Daiichi Sankyo globally. HOKUSAI-VTE(VTE) P3 studies will be presented at ESC 2013.</li> <li>• ENGAGE AF-TIMI 48(AF) P3 study will be presented at the major medical congress in FY2013.</li> <li>• NDA for AF/VTE indication to be expected in FY2013.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-747	prasugrel	Oral	Anti-platelet agent	Ischemic heart disease undergoing PCI Ischemic stroke Sickle cell disease	Daiichi Sankyo Ube Industries	Effient (US, Asia) Efiect (EU)
<ul style="list-style-type: none"> <li>• Inhibition of platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface.</li> <li>• Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan.</li> <li>• A P3 study in pediatric sickle cell disease patients is on-going in US.</li> <li>• [EU] Approved in Feb-2009 for ACS-PCI. Brand name: Efiect</li> <li>• [US] Approved in Jul-2009 for ACS-PCI. Brand name: Effient</li> <li>• [JP] Filed in Jun-2013 for the ischemic heart disease undergoing PCI. P3 studies for ischemic stroke are on-going.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-3150	-	Oral	MR antagonist	Hypertension Diabetic nephropathy	Exelixis	TBD
<ul style="list-style-type: none"> <li>• Inhibitor of MR (mineralocorticoid receptor) binding to aldosterone to show antihypertensive and organ-protective effect</li> <li>• The P2 study in essential hypertension and P2 study in diabetes with albuminuria are ongoing in Japan.</li> </ul>						

## Oncology

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
ARQ 197	tivantinib	Oral	Met inhibitor	Hepatocellular cancer Colorectal cancer	ArQule	TBD
<ul style="list-style-type: none"> <li>• Met has multiple roles in intracellular signal transductions such as cancer cell motility, proliferation, angiogenesis, invasion, and apoptosis induction.</li> <li>• Variations of c-Met are shown in gastric, HCC, head and neck cancer, and high expression of c-met are shown in colon, HCC, pancreatic, prostate, breast cancer, etc.</li> <li>• A P3 clinical study for HCC was started in Jan-2013.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-1008	tigatuzumab	Injection	Anti-DR5 antibody	Hepatocellular cancer	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> <li>• A humanized version TRA-8, a murine agonistic Mab raised against human death receptor 5(DR5).</li> <li>• DR5 is rarely expressed in normal tissues, expected to show selective activity against tumor cells.</li> <li>• Induces apoptosis of tumor cells expressing DR5 on the cell surface.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DE-766	nimotuzumab	Injection	Anti-EGFR antibody	Gastric cancer Non small cell lung cancer Esophageal cancer	CIMYM Biosciences	TBD
<ul style="list-style-type: none"> <li>• A humanized monoclonal antibody against Epidermal Growth Factor Receptor(EGFR).</li> <li>• Expected to be a best in class EGFR antibody, safety against the skin toxicity and the efficacy comparable to the other EGFR antibodies.</li> <li>• P3 in Japan for NSCLC started in March 2013, that for Gastric cancer started in April</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
U3-1287	patritumab	Injection	Anti-HER3 antibody	Non small cell lung cancer Breast cancer	Daiichi Sankyo (U3 Pharma)	TBD
<ul style="list-style-type: none"> <li>•HER3 is one of the member of the Epidermal Growth Factor Receptor(EGFR) family of proteins.</li> <li>•HER3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce cell proliferation than homodimers of HER2 or EGFR</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX4032	vemurafenib	Oral	BRAF inhibitor	Thyroid cancer	Daiichi Sankyo (Plexikon)	Zelboraf
<ul style="list-style-type: none"> <li>•Plexikon discovered vemurafenib, and since 2006, has been co-developing it with partner, Roche</li> <li>•Personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX3397	-	Oral	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma Acute myeloid leukemia Glioblastoma Prostate Cancer	Daiichi Sankyo (Plexikon)	TBD
<ul style="list-style-type: none"> <li>•Plexikon discovered PLX3397.</li> <li>•Clinical studies are on-going for several types of cancer.</li> </ul>						

## Others

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
AMG 162	denosumab	Injection	Anti-RANKL antibody	Breast cancer adjuvant Rheumatoid arthritis Giant cell tumor	Amgen	SRE: Ranmark(JP) Osteoporosis: Pralia(JP)
<ul style="list-style-type: none"> <li>• Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the resorptive phase of bone remodeling.</li> <li>• July, 2007 In-licensed from Amgen</li> <li>• P3 : Breast cancer adjuvant, P2: Rheumatoid arthritis, Giant cell tumor of bone</li> <li>• [JP] NDA approval: Skeletal Related Event(SRE) in Jan-2012, Osteoporosis in Mar-2013</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-8958	Ianinamivir	Inhalant	Neuraminidase inhibitor	Influenza, Treatment / Prophylactic	Daiichi Sankyo	Inavir(JP)
<ul style="list-style-type: none"> <li>• Long-acting neuraminidase inhibitor</li> <li>• Licensing activity with Biota in the US and EU, development by Daiichi Sankyo in Japan</li> <li>• CS-8958 is under development as an inhalant that will act directly on the pulmonary and tracheal sites of infection.</li> <li>• [JP] Application: Prophylactic in Nov-2012</li> <li>• [JP] Approved for the flu treatment: Sep-2010. Brand name: Inavir</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DR-3355	levofloxacin	Injection	New quinolone	Anti-infection	Daiichi Sankyo	Cravit (JP) Levaquin (US) Tavanic (EU)
<ul style="list-style-type: none"> <li>• As LCM, additional indications of urinary tract infection, surgical infection and gynecological infection, which are the largest market next to respiratory tract infection are under development.</li> <li>• A P3 comparative study for urinary tract infection and 4 open studies are on-going.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DS-5565	-	Oral	$\alpha 2\delta$ ligand	Chronic pain	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> <li>• An <math>\alpha 2\delta</math> ligand that binds to <math>\alpha 2\delta</math> subunit of voltage-dependent <math>Ca^{2+}</math> channels</li> <li>• Considered to decrease excess <math>Ca^{2+}</math> influx to nerve terminals and to lower pain-related neurotransmitter release.</li> <li>• Clinical studies are on-going for diabetic peripheral neuropathic pain</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
SUN13837	-	Injection	Modulator of bFGF signaling system	Spinal cord injury	Daiichi Sankyo (Asubio Pharma)	TBD
<ul style="list-style-type: none"> <li>• Although SUN13837 acts upon the signal coupled with the FGF receptor and shows similar cell differentiation actions (nerve cell protection, nerve axon elongation) to bFGF, it does not show any cell multiplication function.</li> <li>• By accelerating self-regeneration capabilities (nerve cell protection, nerve axon elongation) with bFGF like cell differentiation actions, the perceptual and motor-functional dysfunctions caused by cord injuries are to be improved</li> <li>• By making perceptual and motor-functional dysfunctions recovered at an early stage of postinjury, remnant functions in the chronic period are to be improved</li> <li>• Clinical studies are on-going for patients with severe spinal cord injury</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
ASB17061	-	Oral	Chymase inhibitor	Atopic Dermatitis	Daiichi Sankyo (Asubio Pharma)	TBD
<ul style="list-style-type: none"> <li>• Inhibiting chymase, one of endogenous proteases, which is released from mast cells and involves allergic reaction.</li> <li>• Expected to be an oral anti-atopic dermatitis drug with a novel mechanism of action treated with QD dosing.</li> <li>• Clinical study is on-going for adult patients with atopic dermatitis.</li> </ul>						

# MEMO

(This page is intentionally left blank)

**1. Summary of Consolidated Income Statement (FY2012)**

JPY Bn	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>242.6</b>	<b>+4.7%</b>	<b>100%</b>	<b>241.6</b>	<b>+7.7%</b>	<b>100%</b>	<b>261.5</b>	<b>+8.8%</b>	<b>100%</b>	<b>252.2</b>	<b>+4.1%</b>	<b>100%</b>	<b>997.9</b>	<b>59.2</b>	<b>+6.3%</b>
Cost of sales	27%	66.7	+11.2%	32%	77.2	+11.9%	33%	86.4	+20.6%	33%	83.4	+22.6%	31%	313.7	45.0	+16.8%
Gross Profit	73%	176.0	+2.5%	68%	164.4	+5.8%	67%	175.1	+3.8%	67%	168.8	-3.1%	69%	684.2	14.1	+2.1%
SG&A expenses	59%	143.4	+11.8%	58%	139.8	+2.3%	53%	138.6	-0.3%	64%	161.8	-3.6%	58%	583.7	11.8	+2.1%
R&D expenses	17%	42.0	+2.5%	19%	45.2	+5.1%	17%	44.6	-0.3%	20%	51.2	-8.9%	18%	183.0	-2.0	-1.1%
A&P expenses	9%	22.7	+9.6%	9%	21.6	-8.9%	10%	25.3	+2.0%	11%	27.2	+2.7%	10%	96.8	1.1	+1.1%
Personnel expenses	14%	34.7	-0.4%	14%	34.2	-4.1%	13%	34.1	+1.2%	16%	40.7	+17.0%	14%	143.7	4.7	+3.4%
Other SG&A expenses	18%	44.0	+39.0%	16%	38.9	+13.1%	13%	34.6	-3.2%	17%	42.7	-15.2%	16%	160.2	8.0	+5.3%
<b>Operating Income</b>	<b>13%</b>	<b>32.5</b>	<b>-25.2%</b>	<b>10%</b>	<b>24.6</b>	<b>+31.2%</b>	<b>14%</b>	<b>36.5</b>	<b>+22.9%</b>	<b>3%</b>	<b>7.0</b>	<b>+10.2%</b>	<b>10%</b>	<b>100.5</b>	<b>2.3</b>	<b>+2.4%</b>
Non-operating income / expenses		8.3			-15.5			9.4			-3.5			-1.4	20.6	
Non-operating income		10.3			-5.3			8.1			4.5			17.6	7.6	
Non-operating expenses		2.0			10.2			-1.2			8.0			19.0	-13.0	
<b>Ordinary Income</b>	<b>17%</b>	<b>40.8</b>	<b>-9.0%</b>	<b>4%</b>	<b>9.0</b>	<b>-58.0%</b>	<b>18%</b>	<b>45.8</b>	<b>+128.3%</b>	<b>1%</b>	<b>3.5</b>	<b>-</b>	<b>10%</b>	<b>99.1</b>	<b>22.9</b>	<b>+30.1%</b>
Extraordinary income / losses		0.6			-5.2			-5.7			3.3			-7.1	35.2	
Extraordinary income		2.0			0.5			0.7			8.9			12.1	-2.7	
Extraordinary losses		1.5			5.7			6.4			5.7			19.2	-37.9	
Income before income taxes and minority interests	17%	41.4	-5.5%	2%	3.8	-79.1%	15%	40.2	-	3%	6.7	-	9%	92.1	58.2	+171.5%
Income taxes / minority interests		21.0			-0.1			13.0			-8.4			25.5	1.9	
Income taxes		16.8			3.0			10.2			-6.0			23.9	-15.9	
Minority interests		4.2			-3.1			2.8			-2.4			1.6	17.8	
<b>Net Income</b>	<b>8%</b>	<b>20.4</b>	<b>-19.4%</b>	<b>2%</b>	<b>4.0</b>	<b>-66.3%</b>	<b>10%</b>	<b>27.1</b>	<b>-</b>	<b>6%</b>	<b>15.1</b>	<b>-</b>	<b>7%</b>	<b>66.6</b>	<b>56.2</b>	<b>+541.6%</b>
Effective tax rate		41%			78%			25%			-90%			26%		
Overseas sales ratio results		54%			48%			44%			49%			49%		

**2. Currency Rate (FY2012)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2012	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	80.21	79.42	80.01	83.11	83.11	+4.04
EUR/JPY (average)	102.91	100.64	102.18	107.15	107.15	-1.81
INR/JPY (average)	1.59	1.54	1.50	1.50	1.50	-0.23



**3. Segment Information (FY2012)**

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		183.5	-4.4%		193.9	+4.3%		223.1	+9.0%		211.9	+17.3%		812.4	49.2	+6.5%
Inter-segment sales		0.3			0.3			0.7			0.5			1.8	1.3	
<b>Net sales</b>	<b>100%</b>	<b>183.8</b>	<b>-4.2%</b>	<b>100%</b>	<b>194.2</b>	<b>+4.4%</b>	<b>100%</b>	<b>223.8</b>	<b>+9.2%</b>	<b>100%</b>	<b>212.4</b>	<b>+17.6%</b>	<b>100%</b>	<b>814.2</b>	<b>50.6</b>	<b>+6.6%</b>
Cost of sales	26%	47.9	+16.4%	29%	56.1	+16.2%	30%	67.3	+28.1%	29%	61.2	+35.5%	29%	232.5	45.3	+24.2%
Gross Profit	74%	135.9	-9.9%	71%	138.1	+0.3%	70%	156.5	+2.6%	71%	151.1	+11.6%	71%	581.7	5.2	+0.9%
SG&A expenses	63%	115.9	+4.2%	61%	117.8	-1.1%	54%	121.8	-0.4%	67%	142.3	+1.5%	61%	497.8	4.9	+1.0%
R&D expenses	22%	40.3	+3.1%	22%	43.2	+5.4%	19%	42.8	+0.2%	23%	49.3	-9.2%	22%	175.5	-1.4	-0.8%
Other expenses	41%	75.6	+4.8%	38%	74.6	-4.5%	35%	79.0	-0.8%	44%	93.0	+8.2%	40%	322.2	6.3	+2.0%
<b>Operating Income</b>	<b>11%</b>	<b>20.1</b>	<b>-49.3%</b>	<b>10%</b>	<b>20.3</b>	<b>+8.9%</b>	<b>16%</b>	<b>34.7</b>	<b>+15.1%</b>	<b>4%</b>	<b>8.9</b>	<b>-</b>	<b>10%</b>	<b>84.0</b>	<b>0.3</b>	<b>+0.4%</b>
Non-operating income		2.1			1.0			2.5			1.7			7.3	-0.8	
Non-operating expenses		1.0			1.6			1.2			1.8			5.6	0.8	
<b>Ordinary Income</b>	<b>11%</b>	<b>21.1</b>	<b>-49.2%</b>	<b>10%</b>	<b>19.8</b>	<b>+4.2%</b>	<b>16%</b>	<b>36.1</b>	<b>+16.1%</b>	<b>4%</b>	<b>8.8</b>	<b>-</b>	<b>11%</b>	<b>85.7</b>	<b>-1.3</b>	<b>-1.4%</b>
Extraordinary income		2.0			0.4			0.6			8.9			11.9	-2.4	
Extraordinary losses		1.3			5.7			6.3			2.5			15.8	0.1	
Income before income taxes and minority interests	12%	21.8	-46.2%	7%	14.5	-8.3%	14%	30.4	+2.8%	7%	15.2	-	10%	81.8	-3.8	-4.4%
Income taxes		8.1			4.4			6.9			-4.7			14.7	-36.6	
Minority interests		-0.1			-0.0			0.2			-0.0					
<b>Net Income</b>	<b>7%</b>	<b>13.7</b>	<b>-40.1%</b>	<b>5%</b>	<b>10.2</b>	<b>-4.6%</b>	<b>10%</b>	<b>23.2</b>	<b>+110.3%</b>	<b>9%</b>	<b>19.9</b>	<b>-</b>	<b>8%</b>	<b>67.0</b>	<b>29.7</b>	<b>+79.4%</b>

Ranbaxy Group		Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	
Sales to outside customers		59.1	+48.7%		47.6	+24.0%		38.3	+7.5%		40.3	-34.6%		185.4	9.9	+5.7%	
Inter-segment sales		0.7			0.3			0.3			0.4			1.7	0.6		
<b>Net sales</b>	<b>100%</b>	<b>59.8</b>	<b>+49.5%</b>	<b>100%</b>	<b>47.9</b>	<b>+24.1%</b>	<b>100%</b>	<b>38.6</b>	<b>+7.5%</b>	<b>100%</b>	<b>40.8</b>	<b>-34.3%</b>	<b>100%</b>	<b>187.1</b>	<b>10.5</b>	<b>+6.0%</b>	
Cost of sales	33%	19.5	+3.7%	45%	21.5	+3.7%	52%	20.1	+3.0%	56%	22.9	+0.6%	45%	83.9	2.2	+2.7%	
Gross Profit	67%	40.3	+90.0%	55%	26.5	+47.7%	48%	18.5	+12.9%	44%	17.9	-54.5%	55%	103.2	8.4	+8.8%	
SG&A expenses	44%	26.5	+66.2%	44%	20.9	+28.3%	41%	15.7	+0.5%	45%	18.4	-31.2%	44%	81.4	6.9	+9.3%	
R&D expenses	3%	2.0	-12.3%	4%	2.1	-10.7%	5%	1.9	-17.0%	5%	2.1	-11.6%	4%	8.1	-1.2	-12.9%	
Other expenses	41%	24.5	+79.4%	39%	18.7	+35.1%	36%	13.8	+3.6%	40%	16.3	-33.0%	39%	73.3	8.1	+12.5%	
<b>Operating Income</b>	<b>23%</b>	<b>13.8</b>	<b>+161.9%</b>	<b>12%</b>	<b>5.6</b>	<b>+238.2%</b>	<b>7%</b>	<b>2.9</b>	<b>+238.4%</b>	<b>-1%</b>	<b>-0.5</b>	<b>-103.9%</b>	<b>12%</b>	<b>21.8</b>	<b>1.4</b>	<b>+7.0%</b>	
Non-operating income		8.3			-6.2			5.7			2.8			10.4	7.3		
Non-operating expenses		0.8			8.6			-2.5			6.2			13.2	-13.9		
<b>Ordinary Income</b>	<b>36%</b>	<b>21.2</b>	<b>+269.3%</b>	<b>-19%</b>	<b>-9.2</b>	<b>-317.5%</b>	<b>29%</b>	<b>11.0</b>	<b>-</b>	<b>-10%</b>	<b>-3.9</b>	<b>-</b>	<b>10%</b>	<b>19.1</b>	<b>22.6</b>	<b>-</b>	
Extraordinary income		0.0			0.0			0.0			0.0			0.1	-0.9		
Extraordinary losses		0.1			-0.0			0.0			3.2			3.4	-38.0		
Income before income taxes and minority interests	35%	21.1	+267.8%	-19%	-9.2	-321.2%	29%	11.0	-	-17%	-7.1	-	9%	15.9	59.6	-	
Income taxes		6.1			-2.3			3.6			-1.1			6.3	16.5		
Minority interests		0.0			0.0			0.1			0.1			0.2	0.0		
<b>Net Income</b>	<b>25%</b>	<b>15.0</b>	<b>+118.9%</b>	<b>-14%</b>	<b>-6.9</b>	<b>-297.1%</b>	<b>19%</b>	<b>7.4</b>	<b>-</b>	<b>-15%</b>	<b>-6.1</b>	<b>-</b>	<b>5%</b>	<b>9.4</b>	<b>43.1</b>	<b>-</b>	

**Inter-segment Transactions**

<b>Net sales</b>		<b>-1.0</b>			<b>-0.6</b>			<b>-1.0</b>			<b>-0.9</b>			<b>-3.5</b>		
Cost of sales		-0.7			-0.4			-0.9			-0.7			-2.7		
Gross Profit		-0.3			-0.2			-0.0			-0.2			-0.7		
SG&A expenses		1.1			1.2			1.1			1.2			4.6		
R&D expenses		-0.3			-0.1			-0.1			-0.1			-0.6		
Other expenses		1.4			1.3			1.3			1.3			5.2		
<b>Operating Income</b>		<b>-1.4</b>			<b>-1.4</b>			<b>-1.1</b>			<b>-1.4</b>			<b>-5.3</b>		
Non-operating income		-0.0			-0.1			-0.1			0.0			-0.2		
Non-operating expenses		0.1			0.0			0.0			0.0			0.2		
<b>Ordinary Income</b>		<b>-1.5</b>			<b>-1.5</b>			<b>-1.2</b>			<b>-1.4</b>			<b>-5.7</b>		
Extraordinary income		-			0.0			0.0			0.1			0.1		
Extraordinary losses		0.0			-0.0			0.0			0.0			0.0		
Income before income taxes and minority interests		-1.5			-1.5			-1.2			-1.4			-5.6		
Income taxes		2.6			0.9			-0.3			-0.3			3.0		
Minority interests		4.2			-3.1			2.6			-2.4			1.3		
<b>Net Income</b>		<b>-8.3</b>			<b>0.7</b>			<b>-3.5</b>			<b>1.3</b>			<b>-9.8</b>		

**4. Sales by Business Units (FY2012)**

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	
JPY Bn																	
<b>Consolidated Net Sales</b>	<b>990.0</b>	<b>242.6</b>	<b>+4.7%</b>	<b>25%</b>	<b>241.6</b>	<b>+7.7%</b>	<b>24%</b>	<b>261.5</b>	<b>+8.8%</b>	<b>26%</b>	<b>252.2</b>	<b>+4.1%</b>	<b>26%</b>	<b>997.9</b>	<b>+6.3%</b>	<b>101%</b>	
<b>Japan Company (domestic sales)</b>	<b>440.0</b>	<b>98.2</b>	<b>-2.2%</b>	<b>22%</b>	<b>106.9</b>	<b>+6.3%</b>	<b>24%</b>	<b>124.7</b>	<b>+9.5%</b>	<b>28%</b>	<b>112.7</b>	<b>+18.8%</b>	<b>26%</b>	<b>442.5</b>	<b>+8.0%</b>	<b>101%</b>	
Olmotec	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%	
Rezaltas	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%	
Calblock	10.0	2.7	-14.0%	27%	2.8	-12.9%	28%	2.8	-13.8%	28%	2.6	-5.5%	26%	10.9	-11.8%	109%	
Loxonin	60.0	14.1	-2.0%	24%	15.6	-0.4%	26%	16.2	-6.1%	27%	13.7	+0.0%	23%	59.6	-2.3%	99%	
Cravit	35.0	8.1	-4.2%	23%	8.4	+0.0%	24%	10.6	-2.0%	30%	8.8	+1.6%	25%	35.9	-1.2%	103%	
Nexium	22.0	1.7	-	8%	2.7	+7.1%	13%	8.3	+1254.8%	38%	8.9	+1113.9%	40%	21.6	+452.0%	98%	
Memary	26.0	5.1	+128.7%	20%	5.6	+247.5%	22%	6.6	+135.7%	25%	6.4	+103.0%	25%	23.8	+142.0%	92%	
Mevalotin	26.0	6.5	-25.7%	25%	6.8	-21.8%	26%	6.6	-25.6%	25%	6.0	-12.4%	23%	25.8	-21.9%	99%	
Artist	22.0	5.6	-8.9%	25%	5.6	-9.3%	26%	5.8	-10.9%	27%	5.3	-5.6%	24%	22.4	-8.8%	102%	
Omnipaque	20.0	4.9	-13.2%	25%	5.3	-15.9%	26%	5.4	-16.3%	27%	4.6	-11.1%	23%	20.2	-14.3%	101%	
Urief	11.0	2.7	+0.5%	24%	2.8	+0.1%	25%	3.0	-1.8%	27%	2.7	+5.7%	25%	11.1	+1.0%	101%	
Inavir	11.0	0.4	+10.3%	4%	0.1	-164.9%	1%	2.1	+22.9%	19%	8.6	-2.0%	78%	11.1	+3.8%	101%	
Ranmark	5.0	0.6	-	12%	1.1	-	22%	1.3	-	27%	1.4	-	27%	4.4	-	88%	
Vaccines	not disclosed	5.2	+13.9%	-	8.1	+52.5%	-	11.8	+72.2%	-	4.7	+3.5%	-	29.8	+40.2%	-	
Daiichi Sankyo Espha products	not disclosed	2.8	+16.2%	-	2.7	+12.7%	-	3.0	+2.4%	-	2.6	+20.7%	-	11.1	+12.2%	-	
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>48.0</b>	<b>10.2</b>	<b>+5.0%</b>	<b>21%</b>	<b>12.8</b>	<b>+1.1%</b>	<b>27%</b>	<b>14.5</b>	<b>+6.1%</b>	<b>30%</b>	<b>9.5</b>	<b>-2.4%</b>	<b>20%</b>	<b>47.1</b>	<b>+2.7%</b>	<b>98%</b>	
<b>Daiichi Sankyo, Inc. (US)</b>	<b>139.0</b>	<b>35.9</b>	<b>+3.7%</b>	<b>26%</b>	<b>32.6</b>	<b>+10.0%</b>	<b>24%</b>	<b>37.4</b>	<b>+23.9%</b>	<b>27%</b>	<b>36.4</b>	<b>+11.6%</b>	<b>26%</b>	<b>142.3</b>	<b>+12.0%</b>	<b>102%</b>	
Olmesartan	93.0	23.9	-3.8%	26%	21.7	+6.3%	23%	25.7	+24.9%	28%	23.6	+7.0%	25%	94.9	+7.9%	102%	
Benicar/Benicar HCT	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%	
Azor	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%	
Tribenzor	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%	
Welchol	31.0	8.3	+17.5%	27%	7.2	+10.5%	23%	8.3	+26.1%	27%	9.3	+39.4%	30%	33.1	+23.4%	107%	
Effient (alliance revenue)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-	
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>38.0</b>	<b>11.3</b>	<b>-10.9%</b>	<b>30%</b>	<b>7.7</b>	<b>-17.4%</b>	<b>20%</b>	<b>11.3</b>	<b>-24.7%</b>	<b>30%</b>	<b>8.2</b>	<b>+7.7%</b>	<b>22%</b>	<b>38.6</b>	<b>-13.7%</b>	<b>102%</b>	
Venofer	23.0	6.8	-7.4%	30%	3.8	-30.4%	17%	8.3	-8.5%	36%	4.7	+60.9%	20%	23.6	-4.9%	103%	
<b>Daiichi Sankyo Europe GmbH</b>	<b>65.0</b>	<b>13.9</b>	<b>-17.6%</b>	<b>21%</b>	<b>15.1</b>	<b>-10.8%</b>	<b>23%</b>	<b>16.9</b>	<b>-2.6%</b>	<b>26%</b>	<b>18.5</b>	<b>-3.0%</b>	<b>29%</b>	<b>64.4</b>	<b>-8.3%</b>	<b>99%</b>	
Olmesartan	48.0	9.9	-16.6%	21%	11.3	-6.6%	24%	12.9	+1.8%	27%	13.9	-3.1%	29%	48.0	-5.9%	100%	
Olmotec/Olmotec Plus	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%	
Sevikar	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%	
Sevikar HCT	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%	
Efient (alliance revenue)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-	
<b>Asia, South and Central America (ASCA)<sup>1</sup></b>	<b>38.0</b>	<b>7.1</b>	<b>+9.8%</b>	<b>19%</b>	<b>8.1</b>	<b>+10.1%</b>	<b>21%</b>	<b>8.2</b>	<b>+18.4%</b>	<b>22%</b>	<b>17.1</b>	<b>+117.8%</b>	<b>45%</b>	<b>40.5</b>	<b>+41.6%</b>	<b>107%</b>	
Daiichi Sankyo China <sup>2</sup>	not disclosed	2.7	+0.9%	-	3.0	+16.0%	-	3.1	+50.9%	-	7.6	+214.7%	-	16.4	+68.8%	-	
Daiichi Sankyo Taiwan	not disclosed	0.8	-5.9%	-	0.8	-1.3%	-	0.8	+7.8%	-	0.9	+19.5%	-	3.3	+4.7%	-	
Daiichi Sankyo Korea	not disclosed	1.2	+2.1%	-	1.2	+5.5%	-	1.3	+16.8%	-	1.6	+40.0%	-	5.3	+15.8%	-	
Daiichi Sankyo (Thailand)	not disclosed	0.3	+3.7%	-	0.3	+2.7%	-	0.4	+14.5%	-	0.4	+38.7%	-	1.4	+15.6%	-	
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.2	+14.2%	-	1.2	-22.5%	-	1.0	-34.4%	-	3.2	+118.5%	-	6.6	+18.6%	-	
Daiichi Sankyo Venezuela	not disclosed	0.8	+87.0%	-	1.4	+49.5%	-	1.5	+37.1%	-	2.9	+75.9%	-	6.7	+60.7%	-	
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	0.1	-	-	0.1	-	-	0.1	-	-	0.4	-	-	0.7	-	-	
<b>Ranbaxy Laboratories Limited</b>	<b>179.0</b>	<b>59.1</b>	<b>+48.7%</b>	<b>33%</b>	<b>47.6</b>	<b>+24.0%</b>	<b>27%</b>	<b>38.3</b>	<b>+7.5%</b>	<b>21%</b>	<b>40.3</b>	<b>-34.6%</b>	<b>23%</b>	<b>185.4</b>	<b>+5.7%</b>	<b>104%</b>	
<b>Others</b>	<b>43.0</b>	<b>6.8</b>	<b>-38.0%</b>	<b>16%</b>	<b>10.7</b>	<b>+13.1%</b>	<b>25%</b>	<b>10.0</b>	<b>+32.8%</b>	<b>23%</b>	<b>9.5</b>	<b>+7.5%</b>	<b>22%</b>	<b>37.1</b>	<b>+0.5%</b>	<b>86%</b>	
Levofloxacin export, royalty, etc	3.0	1.2	-60.1%	41%	1.0	-56.6%	34%	1.4	+19.3%	46%	0.6	-59.6%	21%	4.3	-47.8%	142%	
Plexxikon	not disclosed	0.1	-96.1%	-	1.4	-24.6%	-	1.0	+313.4%	-	0.5	-35.9%	-	3.1	-47.7%	-	

**[Reference] Sales in Local Currency**

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012		
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn																
<b>Daiichi Sankyo, Inc. (US)</b>	<b>1,711</b>	<b>448</b>	<b>+5.7%</b>	<b>26%</b>	<b>415</b>	<b>+8.7%</b>	<b>24%</b>	<b>461.0</b>	<b>+18.2%</b>	<b>27%</b>	<b>389.0</b>	<b>-5.6%</b>	<b>23%</b>	<b>1,713</b>	<b>+6.5%</b>	<b>100%</b>
Olmesartan	1,144	298	-2.0%	26%	276	+4.9%	24%	317	+19.0%	28%	251	-9.9%	22%	1,142	+2.7%	100%
Benicar/Benicar HCT	898	235	-4.5%	26%	213	-1.8%	24%	249	+18.8%	28%	184	-19.6%	20%	881	-2.2%	98%
Azor	172	44	+0.2%	25%	44	+37.4%	26%	47	+15.5%	27%	44	+22.2%	25%	179	+17.3%	104%
Tribenzor	75	19	+33.3%	26%	19	+33.0%	26%	20	+30.9%	27%	23	+66.5%	31%	82	+40.6%	109%
Welchol	388	103	+19.7%	27%	92	+9.5%	24%	103	+20.3%	27%	101	+19.8%	26%	399	+17.4%	103%
Effient (alliance revenue)	not disclosed	30	+54.7%	-	30	+35.4%	-	34	+41.2%	-	33	-5.7%	-	127	+26.2%	-
USD Mn																
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>468</b>	<b>141</b>	<b>-9.2%</b>	<b>30%</b>	<b>98</b>	<b>-18.5%</b>	<b>21%</b>	<b>140.0</b>	<b>-27.6%</b>	<b>30%</b>	<b>85.0</b>	<b>-11.8%</b>	<b>18%</b>	<b>465</b>	<b>-17.9%</b>	<b>99%</b>
Venofer	288	85	-5.6%	30%	49	-31.0%	17%	103	-11.8%	36%	47	+29.8%	16%	284	-9.6%	99%
EUR Mn																
<b>Daiichi Sankyo Europe GmbH</b>	<b>650</b>	<b>135</b>	<b>-6.0%</b>	<b>21%</b>	<b>153</b>	<b>-0.2%</b>	<b>24%</b>	<b>161.0</b>	<b>-2.6%</b>	<b>25%</b>	<b>152.0</b>	<b>-16.6%</b>	<b>23%</b>	<b>601</b>	<b>-6.7%</b>	<b>93%</b>
Olmesartan	480	96	-4.8%	20%	115	+4.4%	24%	123	+2.0%	26%	114	-16.5%	24%	448	-4.3%	93%
Olmetec/Olmetec Plus	340	62	-16.2%	18%	82	+3.1%	24%	82	-6.8%	24%	78	-17.8%	23%	304	-9.6%	89%
Sevikar	100	24	+19.3%	25%	23	-1.1%	24%	29	+17.7%	29%	23	-26.4%	23%	100	-0.3%	100%
Sevikar HCT	40	9	+50.1%	24%	9	+41.0%	23%	12	+49.4%	30%	13	+27.1%	32%	44	+40.5%	109%
Efient (alliance revenue)	not disclosed	9	+76.5%	-	9	+57.9%	-	9	+33.5%	-	10	-1.0%	-	36	+34.1%	-
INR Bn																
<b>Ranbaxy Laboratories Limited</b>	<b>105</b>	<b>37</b>	<b>+71.1%</b>	<b>35%</b>	<b>32</b>	<b>+53.1%</b>	<b>31%</b>	<b>27.0</b>	<b>+31.2%</b>	<b>26%</b>	<b>27.0</b>	<b>-28.9%</b>	<b>26%</b>	<b>124</b>	<b>+21.9%</b>	<b>117%</b>

**5. Sales of Global Products (FY2012)**

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012		
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn																
<b>Olmesartan</b>	<b>251.0</b>	<b>60.0</b>	<b>-5.3%</b>	<b>24%</b>	<b>60.8</b>	<b>+0.6%</b>	<b>24%</b>	<b>68.3</b>	<b>+6.4%</b>	<b>27%</b>	<b>69.7</b>	<b>+13.0%</b>	<b>28%</b>	<b>258.9</b>	<b>+3.7%</b>	<b>103%</b>
Olmetec (JPN)	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%
Rezaltas (JPN)	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%
Benicar/Benicar HCT (US)	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%
Azor (US)	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%
Tribenzor (US)	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%
Olmetec/Olmetec Plus (EU)	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%
Sevikar (EU)	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%
Sevikar HCT (EU)	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%
Other subsidiaries, export, etc	18.0	4.0	+20.6%	22%	4.3	+0.1%	24%	4.3	-3.1%	24%	8.1	+82.8%	45%	20.7	+25.7%	115%
<b>Prasugrel</b>	<b>not disclosed</b>	<b>3.3</b>	<b>+52.6%</b>	<b>-</b>	<b>3.2</b>	<b>+37.5%</b>	<b>-</b>	<b>3.7</b>	<b>+43.5%</b>	<b>-</b>	<b>4.2</b>	<b>+10.4%</b>	<b>-</b>	<b>14.4</b>	<b>+32.5%</b>	<b>-</b>
Effient alliance revenue (US)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-
Efient alliance revenue (EU)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-

**1. Summary of Consolidated Income Statement (FY2011)**

JPY Bn	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>231.7</b>	<b>-9.7%</b>	<b>100%</b>	<b>224.4</b>	<b>-7.5%</b>	<b>100%</b>	<b>240.4</b>	<b>-3.5%</b>	<b>100%</b>	<b>242.3</b>	<b>+10.5%</b>	<b>100%</b>	<b>938.7</b>	<b>-28.7</b>	<b>-3.0%</b>
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%
<b>Operating Income</b>	<b>19%</b>	<b>43.5</b>	<b>-28.8%</b>	<b>8%</b>	<b>18.7</b>	<b>-35.6%</b>	<b>12%</b>	<b>29.7</b>	<b>-2.8%</b>	<b>3%</b>	<b>6.3</b>	<b>+318.5%</b>	<b>10%</b>	<b>98.2</b>	<b>-23.9</b>	<b>-19.6%</b>
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2	
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4	
<b>Ordinary Income</b>	<b>19%</b>	<b>44.8</b>	<b>-36.0%</b>	<b>10%</b>	<b>21.5</b>	<b>-4.6%</b>	<b>8%</b>	<b>20.1</b>	<b>-47.1%</b>	<b>-4%</b>	<b>-10.2</b>	<b>-</b>	<b>8%</b>	<b>76.2</b>	<b>-55.5</b>	<b>-42.2%</b>
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0	
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9	
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0	
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7	
<b>Net Income</b>	<b>11%</b>	<b>25.3</b>	<b>-23.5%</b>	<b>5%</b>	<b>11.7</b>	<b>-38.5%</b>	<b>-8%</b>	<b>-19.5</b>	<b>-</b>	<b>-3%</b>	<b>-7.2</b>	<b>-</b>	<b>1%</b>	<b>10.4</b>	<b>-59.7</b>	<b>-85.2%</b>
Effective tax rate		37%			34%			-			-			117%		
Overseas sales ratio results		51%			48%			45%			56%			50%		

**2. Currency Rate (FY2011)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07	-6.65
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96	-4.17
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73	-0.20

**3. Segment Information (FY2011)**

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
<b>Net sales</b>	<b>100%</b>	<b>192.0</b>	<b>-4.8%</b>	<b>100%</b>	<b>186.0</b>	<b>-6.4%</b>	<b>100%</b>	<b>205.0</b>	<b>-4.1%</b>	<b>100%</b>	<b>180.6</b>	<b>-0.4%</b>	<b>100%</b>	<b>763.6</b>	<b>-31.8</b>	<b>-4.0%</b>
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
<b>Operating Income</b>	<b>21%</b>	<b>39.6</b>	<b>-8.5%</b>	<b>10%</b>	<b>18.7</b>	<b>-19.4%</b>	<b>15%</b>	<b>30.2</b>	<b>-2.9%</b>	<b>-3%</b>	<b>-4.8</b>	<b>-</b>	<b>11%</b>	<b>83.7</b>	<b>-16.1</b>	<b>-16.2%</b>
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
<b>Ordinary Income</b>	<b>22%</b>	<b>41.6</b>	<b>-4.2%</b>	<b>10%</b>	<b>19.0</b>	<b>-17.8%</b>	<b>15%</b>	<b>31.1</b>	<b>-7.9%</b>	<b>-3%</b>	<b>-4.6</b>	<b>-</b>	<b>11%</b>	<b>87.0</b>	<b>-13.0</b>	<b>-13.0%</b>
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
<b>Net Income</b>	<b>12%</b>	<b>22.9</b>	<b>+2.5%</b>	<b>6%</b>	<b>10.7</b>	<b>-41.9%</b>	<b>5%</b>	<b>11.0</b>	<b>-57.5%</b>	<b>-4%</b>	<b>-7.2</b>	<b>-</b>	<b>5%</b>	<b>37.4</b>	<b>-21.4</b>	<b>-36.4%</b>
<b>Ranbaxy Group</b>																
Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0	
<b>Net sales</b>	<b>100%</b>	<b>40.0</b>	<b>-27.1%</b>	<b>100%</b>	<b>38.6</b>	<b>-11.7%</b>	<b>100%</b>	<b>35.9</b>	<b>+1.1%</b>	<b>100%</b>	<b>62.0</b>	<b>+59.5%</b>	<b>100%</b>	<b>176.6</b>	<b>3.5</b>	<b>+2.0%</b>
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%
<b>Operating Income</b>	<b>13%</b>	<b>5.3</b>	<b>-72.7%</b>	<b>4%</b>	<b>1.7</b>	<b>-74.9%</b>	<b>2%</b>	<b>0.9</b>	<b>+34.5%</b>	<b>20%</b>	<b>12.6</b>	<b>+998.6%</b>	<b>12%</b>	<b>20.4</b>	<b>-7.3</b>	<b>-26.4%</b>
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0	
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1	
<b>Ordinary Income</b>	<b>14%</b>	<b>5.8</b>	<b>-79.6%</b>	<b>11%</b>	<b>4.2</b>	<b>+353.5%</b>	<b>-26%</b>	<b>-9.5</b>	<b>-</b>	<b>-6%</b>	<b>-3.9</b>	<b>-</b>	<b>-2%</b>	<b>-3.4</b>	<b>-43.4</b>	<b>-</b>
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1	
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4	
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1	
<b>Net Income</b>	<b>17%</b>	<b>6.9</b>	<b>-62.7%</b>	<b>9%</b>	<b>3.5</b>	<b>-22.7%</b>	<b>-16%</b>	<b>-5.6</b>	<b>-</b>	<b>-62%</b>	<b>-38.5</b>	<b>-</b>	<b>-19%</b>	<b>-33.7</b>	<b>-57.1</b>	<b>-</b>
<b>Inter-segment Transactions</b>																
<b>Net sales</b>		<b>-0.3</b>			<b>-0.3</b>			<b>-0.6</b>			<b>-0.4</b>			<b>-1.5</b>		
Cost of sales		0.0			-0.1			-0.3			0.1			-0.3		
Gross Profit		-0.3			-0.2			-0.2			-0.5			-1.3		
SG&A expenses		1.1			1.4			1.1			1.0			4.6		
R&D expenses		-0.4			-0.3			-0.3			-0.3			-1.2		
Other expenses		1.4			1.7			1.4			1.3			5.8		
<b>Operating Income</b>		<b>-1.4</b>			<b>-1.6</b>			<b>-1.3</b>			<b>-1.5</b>			<b>-5.9</b>		
Non-operating income		-1.1			-0.1			-0.1			-0.1			-1.3		
Non-operating expenses		0.0			0.0			0.1			0.0			0.1		
<b>Ordinary Income</b>		<b>-2.5</b>			<b>-1.7</b>			<b>-1.5</b>			<b>-1.7</b>			<b>-7.3</b>		
Extraordinary income		0.1			0.0			-0.7			0.0			-0.6		
Extraordinary losses								40.3			-40.3			0.0		
Income before income taxes and minority interests		-2.4			-1.7			-42.5			38.7			-7.9		
Income taxes		-0.3			-0.2			-0.5			-0.2			-1.3		
Minority interests		2.3			1.0			-17.0			0.4			-13.4		
<b>Net Income</b>		<b>-4.4</b>			<b>-2.4</b>			<b>-24.9</b>			<b>38.5</b>			<b>6.7</b>		

**4. Sales by Business Units (FY2011)**

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
<b>Consolidated Net Sales</b>	<b>231.7</b>	<b>-9.7%</b>	<b>24%</b>	<b>224.4</b>	<b>-7.5%</b>	<b>23%</b>	<b>240.4</b>	<b>-3.5%</b>	<b>25%</b>	<b>242.3</b>	<b>+10.5%</b>	<b>25%</b>	<b>938.7</b>	<b>-3.0%</b>	<b>97%</b>
<b>Japan Company (domestic sales)</b>	<b>100.4</b>	<b>-4.6%</b>	<b>23%</b>	<b>100.5</b>	<b>-2.4%</b>	<b>23%</b>	<b>113.9</b>	<b>-2.4%</b>	<b>26%</b>	<b>94.9</b>	<b>+4.3%</b>	<b>22%</b>	<b>409.8</b>	<b>-1.5%</b>	<b>94%</b>
Olmotec	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Calblock	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%
Loxonin	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%
Cravit	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Nexium	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-
Mearny	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-
Mevalotin	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Artist	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%
Omnipaque	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%
Urief	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%
Inavir	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%
Vaccines	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-
Daiichi Sankyo Espha products	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.7</b>	<b>+4.9%</b>	<b>20%</b>	<b>12.7</b>	<b>+8.2%</b>	<b>26%</b>	<b>13.7</b>	<b>+4.1%</b>	<b>28%</b>	<b>9.7</b>	<b>-8.5%</b>	<b>20%</b>	<b>45.9</b>	<b>+2.3%</b>	<b>94%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>34.6</b>	<b>+3.2%</b>	<b>27%</b>	<b>29.7</b>	<b>-12.4%</b>	<b>23%</b>	<b>30.1</b>	<b>-13.0%</b>	<b>23%</b>	<b>32.6</b>	<b>+15.0%</b>	<b>25%</b>	<b>127.1</b>	<b>-2.6%</b>	<b>98%</b>
Olmesartan	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%
Benicar/Benicar HCT	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Welchol	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%
Effient (alliance revenue)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>12.7</b>	<b>-13.6%</b>	<b>26%</b>	<b>9.3</b>	<b>-31.7%</b>	<b>19%</b>	<b>15.0</b>	<b>+31.0%</b>	<b>31%</b>	<b>7.6</b>	<b>-45.6%</b>	<b>16%</b>	<b>44.7</b>	<b>-17.0%</b>	<b>91%</b>
Venofer	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%
<b>Daiichi Sankyo Europe GmbH</b>	<b>16.9</b>	<b>+14.0%</b>	<b>22%</b>	<b>16.9</b>	<b>+2.0%</b>	<b>22%</b>	<b>17.4</b>	<b>-4.3%</b>	<b>23%</b>	<b>19.1</b>	<b>+13.0%</b>	<b>25%</b>	<b>70.2</b>	<b>+5.7%</b>	<b>91%</b>
Olmesartan	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%
Olmotec/Olmotec Plus	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Efient (alliance revenue)	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-
<b>Asia, South and Central America (ASCA)</b>	<b>6.5</b>	<b>+8.7%</b>	<b>22%</b>	<b>7.3</b>	<b>+3.8%</b>	<b>24%</b>	<b>6.9</b>	<b>+2.0%</b>	<b>23%</b>	<b>7.8</b>	<b>+2.8%</b>	<b>26%</b>	<b>28.6</b>	<b>+4.1%</b>	<b>95%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-
Daiichi Sankyo Taiwan	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-
Daiichi Sankyo Korea	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-
Daiichi Sankyo (Thailand)	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-
Daiichi Sankyo Brasil Farmacêutica	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-
Daiichi Sankyo Venezuela	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-
Daiichi Sankyo Mexico S.A. de C.V	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-
<b>Ranbaxy Laboratories Limited</b>	<b>39.8</b>	<b>-27.5%</b>	<b>25%</b>	<b>38.4</b>	<b>-12.0%</b>	<b>24%</b>	<b>35.7</b>	<b>+0.6%</b>	<b>22%</b>	<b>61.6</b>	<b>+62.3%</b>	<b>38%</b>	<b>175.5</b>	<b>+2.1%</b>	<b>108%</b>
<b>Others</b>	<b>11.1</b>	<b>-38.7%</b>	<b>29%</b>	<b>9.5</b>	<b>-25.9%</b>	<b>25%</b>	<b>7.5</b>	<b>-40.5%</b>	<b>20%</b>	<b>8.8</b>	<b>-31.2%</b>	<b>23%</b>	<b>36.9</b>	<b>-34.5%</b>	<b>97%</b>
Levofloxacin export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Plexikon	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-

**[Reference] Sales in Local Currency**

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn															
<b>Daiichi Sankyo, Inc. (US)</b>	<b>424</b>	<b>+16.1%</b>	<b>27%</b>	<b>382</b>	<b>-2.9%</b>	<b>24%</b>	<b>390</b>	<b>-7.5%</b>	<b>25%</b>	<b>412.0</b>	<b>+20.3%</b>	<b>26%</b>	<b>1,608</b>	<b>+5.6%</b>	<b>103%</b>
Olmesartan	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%
Benicar/Benicar HCT	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%
Azor	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%
Tribenzor	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%
Welchol	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%
Effient (alliance revenue)	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-
USD Mn															
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>156</b>	<b>-2.8%</b>	<b>26%</b>	<b>121</b>	<b>-24.2%</b>	<b>21%</b>	<b>193</b>	<b>+36.4%</b>	<b>33%</b>	<b>96.0</b>	<b>-42.8%</b>	<b>16%</b>	<b>566</b>	<b>-10.0%</b>	<b>96%</b>
Venofer	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%
EUR Mn															
<b>Daiichi Sankyo Europe GmbH</b>	<b>144</b>	<b>+13.6%</b>	<b>21%</b>	<b>153</b>	<b>+2.7%</b>	<b>23%</b>	<b>165</b>	<b>+2.5%</b>	<b>25%</b>	<b>182.0</b>	<b>+21.5%</b>	<b>27%</b>	<b>644</b>	<b>+9.8%</b>	<b>96%</b>
Olmesartan	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%
Olmetec/Olmetec Plus	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%
Sevikar	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%
Sevikar HCT	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%
Efient (alliance revenue)	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-
INR Bn															
<b>Ranbaxy Laboratories Limited</b>	<b>22</b>	<b>-21.5%</b>	<b>26%</b>	<b>21</b>	<b>-1.5%</b>	<b>25%</b>	<b>21</b>	<b>+8.0%</b>	<b>25%</b>	<b>38.0</b>	<b>+82.4%</b>	<b>45%</b>	<b>101</b>	<b>+13.9%</b>	<b>119%</b>

**5. Sales of Global Products (FY2011)**

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
<b>Olmesartan</b>	<b>63.3</b>	<b>+5.2%</b>	<b>24%</b>	<b>60.4</b>	<b>-1.6%</b>	<b>22%</b>	<b>64.2</b>	<b>-2.3%</b>	<b>24%</b>	<b>61.7</b>	<b>+13.9%</b>	<b>23%</b>	<b>249.7</b>	<b>+3.4%</b>	<b>93%</b>
Olmetec (JPN)	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas (JPN)	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Benicar/Benicar HCT (US)	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor (US)	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor (US)	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Olmetec/Olmetec Plus (EU)	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar (EU)	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT (EU)	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Other subsidiaries, export, etc	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%
<b>Levofloxacin</b>	<b>13.5</b>	<b>-20.2%</b>	<b>26%</b>	<b>12.8</b>	<b>-24.1%</b>	<b>24%</b>	<b>13.9</b>	<b>-23.3%</b>	<b>26%</b>	<b>12.2</b>	<b>-29.1%</b>	<b>23%</b>	<b>52.4</b>	<b>-24.2%</b>	<b>99%</b>
Cravit (JPN)	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Other subsidiaries	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%
<b>Pravastatin</b>	<b>10.2</b>	<b>-13.9%</b>	<b>27%</b>	<b>10.0</b>	<b>-15.5%</b>	<b>26%</b>	<b>10.6</b>	<b>-8.6%</b>	<b>28%</b>	<b>8.4</b>	<b>-12.6%</b>	<b>22%</b>	<b>39.2</b>	<b>-12.7%</b>	<b>103%</b>
Mevalotin (JPN)	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Other subsidiaries, export, etc	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%
<b>Prasugrel</b>	<b>2.2</b>	<b>+176.5%</b>	<b>-</b>	<b>2.3</b>	<b>+134.2%</b>	<b>-</b>	<b>2.6</b>	<b>+72.6%</b>	<b>-</b>	<b>3.8</b>	<b>+94.3%</b>	<b>-</b>	<b>10.9</b>	<b>+108.2%</b>	<b>-</b>
Effient alliance revenue (US)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Effient alliance revenue (EU)	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-

**1. Summary of Consolidated Income Statement (FY2010)**

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>256.4</b>	<b>+12.9%</b>	<b>100%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>100%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>100%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>100%</b>	<b>967.4</b>	<b>15.3</b>	<b>+1.6%</b>
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
<b>Operating Income</b>	<b>24%</b>	<b>61.1</b>	<b>+128.1%</b>	<b>12%</b>	<b>29.0</b>	<b>+20.6%</b>	<b>12%</b>	<b>30.5</b>	<b>-22.2%</b>	<b>1%</b>	<b>1.5</b>	<b>-72.2%</b>	<b>13%</b>	<b>122.1</b>	<b>26.6</b>	<b>+27.9%</b>
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
<b>Ordinary Income</b>	<b>27%</b>	<b>70.1</b>	<b>+877.7%</b>	<b>9%</b>	<b>22.6</b>	<b>-50.0%</b>	<b>15%</b>	<b>38.0</b>	<b>-1.1%</b>	<b>1%</b>	<b>1.2</b>	<b>-90.7%</b>	<b>14%</b>	<b>131.8</b>	<b>28.6</b>	<b>+27.8%</b>
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
<b>Net Income</b>	<b>13%</b>	<b>33.1</b>	<b>-</b>	<b>8%</b>	<b>19.1</b>	<b>-24.1%</b>	<b>11%</b>	<b>27.5</b>	<b>+33.8%</b>	<b>-4%</b>	<b>-9.5</b>	<b>-</b>	<b>7%</b>	<b>70.1</b>	<b>28.3</b>	<b>+67.5%</b>
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

**2. Currency Rate (FY2010)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72	-7.14
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13	-18.03
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93	-0.02



**3. Segment Information (FY2010)**

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	100%	201.6	+2.1%	100%	198.8	-4.0%	100%	213.7	-2.4%	100%	181.3	-0.3%	100%	795.5	-10.0	-1.2%
Cost of sales	22%	44.9	-1.1%	27%	54.4	+0.1%	26%	55.0	-1.1%	26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%	73%	144.4	-5.4%	74%	158.8	-2.9%	74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%	61%	121.2	-4.2%	60%	127.7	+2.7%	73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%	22%	43.5	-6.9%	24%	50.6	+12.0%	27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%	39%	77.7	-2.6%	36%	77.1	-2.6%	45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
<b>Operating Income</b>	22%	43.3	+44.0%	12%	23.2	-11.6%	15%	31.1	-20.6%	1%	2.3	-1422.3%	13%	99.8	4.6	+4.8%
Non-operating income		1.8			1.9			2.6			0.9			7.2	0.2	
Non-operating expenses		1.7			2.0			-0.1			3.4			7.0	0.9	
<b>Ordinary Income</b>	22%	43.4	+34.8%	12%	23.1	-12.6%	16%	33.7	-12.9%	0%	-0.2	-	13%	100.0	3.8	+4.0%
Extraordinary income		0.8			3.8			1.4			4.3			10.2	5.7	
Extraordinary losses		4.2			1.0			0.7			15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%	13%	25.9	-1.6%	16%	34.4	-8.6%	-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7			7.5			8.5			-3.1			30.6	-23.7	
Minority interests																
<b>Net Income</b>	11%	22.3	+122.8%	9%	18.3	+39.4%	12%	26.0	+30.0%	-4%	-7.8	-	7%	58.8	23.9	+68.6%
<b>Ranbaxy Group</b>																
<b>Net sales</b>	100%	54.9	+84.9%	100%	43.8	+20.1%	100%	35.5	-1.4%	100%	38.9	-12.6%	100%	173.1	26.4	+18.0%
Cost of sales	35%	19.2	+12.0%	46%	20.0	-1.8%	55%	19.5	-1.7%	54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%	54%	23.7	+48.0%	45%	16.0	-1.1%	46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%	39%	17.1	+2.9%	43%	15.4	+5.3%	43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%	7%	3.0	+32.0%	8%	2.8	+19.0%	7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%	32%	14.1	-1.8%	35%	12.5	+2.6%	36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
<b>Operating Income</b>	35%	19.3	-1171.9%	15%	6.6	-1214.7%	2%	0.6	-60.0%	3%	1.1	-83.9%	16%	27.7	21.4	+338.8%
Non-operating income		10.0			-3.0			4.9			4.2			16.2	-5.0	
Non-operating expenses		1.1			2.7			0.1			0.1			3.9	-10.5	
<b>Ordinary Income</b>	52%	28.3	-220.1%	2%	0.9	-95.4%	16%	5.5	+374.9%	14%	5.3	-65.1%	23%	40.0	27.0	+207.8%
Extraordinary income		0.0			5.2			0.0			-0.1			5.1	3.8	
Extraordinary losses		0.7			0.1			1.5			6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%	14%	6.0	-70.2%	11%	4.0	+249.7%	-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2			1.5			0.1			2.4			13.2	3.4	
Minority interests		0.1			0.1			0.1			0.1			0.3	0.1	
<b>Net Income</b>	33%	18.4	-	10%	4.5	-68.3%	11%	3.8	-	-9%	-3.3	-	14%	23.3	19.1	+456.4%
<b>Inter-segment Transactions</b>																
<b>Net sales</b>		-0.1			-0.1			-0.1			-0.9			-1.2		
Cost of sales		0.0			0.0			0.1			0.0			0.1		
Gross Profit		-0.1			-0.1			-0.2			-0.9			-1.3		
SG&A expenses		1.5			0.7			1.0			1.0			4.1		
R&D expenses		0.0			-0.8			-0.4			-0.4			-1.7		
Other expenses		1.5			1.5			1.4			1.4			5.8		
<b>Operating Income</b>		-1.5			-0.7			-1.2			-1.9			-5.4		
Non-operating income		0.0			-0.7			-0.1			0.5			-0.2		
Non-operating expenses					0.1			0.0			2.5			2.6		
<b>Ordinary Income</b>		-1.5			-1.5			-1.3			-3.9			-8.2		
Extraordinary income		0.0			-2.2			-0.5			0.1			-2.5		
Extraordinary losses					0.2			0.0			-5.2			-5.0		
Income before income taxes and minority interests		-1.5			-3.9			-1.7			1.4			-5.7		
Income taxes		-0.3			-0.8			-0.6			-0.2			-2.0		
Minority interests		6.4			0.7			1.1			-0.1			8.2		
<b>Net Income</b>		-7.6			-3.8			-2.2			1.6			-12.0		

**4. Sales by Business Units (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Consolidated Net Sales</b>	<b>256.4</b>	<b>+12.9%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>967.4</b>	<b>+1.6%</b>
<b>Japan Company (domestic sales)</b>	<b>105.3</b>	<b>+0.6%</b>	<b>103.0</b>	<b>-1.7%</b>	<b>116.8</b>	<b>-1.4%</b>	<b>91.0</b>	<b>+7.6%</b>	<b>416.0</b>	<b>+0.9%</b>
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.3</b>	<b>-2.7%</b>	<b>11.7</b>	<b>-12.9%</b>	<b>13.2</b>	<b>+9.1%</b>	<b>10.6</b>	<b>+23.2%</b>	<b>44.8</b>	<b>+2.6%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>33.6</b>	<b>+1.7%</b>	<b>33.9</b>	<b>+1.2%</b>	<b>34.6</b>	<b>+0.6%</b>	<b>28.4</b>	<b>-11.6%</b>	<b>130.5</b>	<b>-1.9%</b>
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>14.7</b>	<b>+10.4%</b>	<b>13.7</b>	<b>+1.3%</b>	<b>11.5</b>	<b>-8.5%</b>	<b>14.0</b>	<b>+10.5%</b>	<b>53.9</b>	<b>+3.5%</b>
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
<b>Daiichi Sankyo Europe GmbH</b>	<b>14.8</b>	<b>-14.6%</b>	<b>16.6</b>	<b>-10.0%</b>	<b>18.1</b>	<b>-5.0%</b>	<b>16.9</b>	<b>-17.2%</b>	<b>66.4</b>	<b>-11.7%</b>
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmotec/Olmotec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
<b>Asia, South and Central America (ASCA)</b>	<b>5.9</b>	<b>+12.7%</b>	<b>7.1</b>	<b>+12.8%</b>	<b>6.8</b>	<b>+3.3%</b>	<b>7.6</b>	<b>-0.4%</b>	<b>27.4</b>	<b>+6.4%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
<b>Ranbaxy Laboratories Limited</b>	<b>54.8</b>	<b>+84.7%</b>	<b>43.7</b>	<b>+19.9%</b>	<b>35.4</b>	<b>-1.6%</b>	<b>38.0</b>	<b>-14.5%</b>	<b>171.9</b>	<b>+17.3%</b>
<b>Others</b>	<b>18.0</b>	<b>+25.6%</b>	<b>12.8</b>	<b>-25.1%</b>	<b>12.7</b>	<b>-20.2%</b>	<b>12.8</b>	<b>-20.0%</b>	<b>56.3</b>	<b>-11.1%</b>
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Efient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

**[Reference] Sales in Local Currency (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
<b>Daiichi Sankyo, Inc. (US)</b>	<b>365</b>	<b>+7.6%</b>	<b>394</b>	<b>+10.2%</b>	<b>422</b>	<b>+10.3%</b>	<b>342</b>	<b>-3.3%</b>	<b>1,522</b>	<b>+6.3%</b>
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>160</b>	<b>+16.7%</b>	<b>159</b>	<b>+10.6%</b>	<b>142</b>	<b>+1.2%</b>	<b>168</b>	<b>+20.1%</b>	<b>629</b>	<b>+12.1%</b>
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
<b>Daiichi Sankyo Europe GmbH</b>	<b>126</b>	<b>-3.2%</b>	<b>149</b>	<b>+8.3%</b>	<b>161</b>	<b>+12.1%</b>	<b>150</b>	<b>-7.0%</b>	<b>587</b>	<b>+2.3%</b>
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmetec/Olmetec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
<b>Ranbaxy Laboratories Limited</b>	<b>28</b>	<b>+76.3%</b>	<b>21</b>	<b>+17.1%</b>	<b>19</b>	<b>+4.6%</b>	<b>21</b>	<b>-9.0%</b>	<b>89</b>	<b>+18.5%</b>

**5. Sales of Global Products (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Olmesartan</b>	<b>60.2</b>	<b>+7.6%</b>	<b>61.4</b>	<b>+3.4%</b>	<b>65.7</b>	<b>+1.6%</b>	<b>54.2</b>	<b>-7.0%</b>	<b>241.5</b>	<b>+1.4%</b>
Olmetec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmetec/Olmetec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
<b>Levofloxacin</b>	<b>17.0</b>	<b>-14.3%</b>	<b>16.9</b>	<b>-28.0%</b>	<b>18.1</b>	<b>-18.3%</b>	<b>17.2</b>	<b>-21.1%</b>	<b>69.1</b>	<b>-20.7%</b>
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
<b>Pravastatin</b>	<b>11.9</b>	<b>-19.1%</b>	<b>11.8</b>	<b>-21.5%</b>	<b>11.6</b>	<b>-21.8%</b>	<b>9.6</b>	<b>-8.3%</b>	<b>44.9</b>	<b>-18.4%</b>
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
<b>Prasugrel (alliance revenue)</b>	<b>0.8</b>	<b>-</b>	<b>1.0</b>	<b>-</b>	<b>1.5</b>	<b>-</b>	<b>2.0</b>	<b>-</b>	<b>5.2</b>	<b>+889.6%</b>
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Efient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%